Prabhudas Lilladher's research report on Sharda Cropchem
Sharda reported better than expected results driven by strong demand from Europe & NAFTA region, new product introduction and better penetration. Declining raw material cost led to 412 bps expansion in gross margin. With improving operating environment, FY21 is expected to be a turnaround year for SHCR with both Europe and NAFTA to be growth levers. Growth momentum is expected to continue driven by expanding distribution reach, new molecule introduction and strong demand for generic molecules. Cushion on gross margin pressure is expected to continue with better availability and reduction in raw material prices.
Outlook
We have increased our Topline/EBITDA/APAT estimates by 1%/3%/1% for FY21, 1%/4%/1% for FY22 and 2%/7%/5% for FY23. Maintain BUY with revised TP of Rs358 (Previous 348) based on 13x Sep’22 earnings.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.